SAB Biotherapeutics (SABS) Assets (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Assets came in at $248.5 million in Q1 2026, up 551.81% YoY from $38.1 million in Q1 2025, and up 43.78% on a QoQ basis from $172.8 million in Q4 2025.
SAB Biotherapeutics (SABS) Assets (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Assets data on file, last reported at $248.5 million in Q1 2026.
- Quarterly Assets rose 551.81% year-over-year to $248.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $248.5 million (up 551.81% YoY) and the FY2025 annual result came in at $172.8 million, up 291.01% from the prior year.
- Assets rose to $248.5 million in Q1 2026, from $172.8 million in the prior quarter.
- In the past five years, Assets ranged from a high of $248.5 million in Q1 2026 to a low of $28.3 million in Q3 2023.
- A 5-year average of $78.0 million and a median of $53.8 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets plunged 55.09% — and 2026, when it surged 551.81%.
- Tracing SABS's Assets over 5 years: stood at $50.9 million in 2022, then surged by 64.9% to $83.9 million in 2023, then tumbled by 47.35% to $44.2 million in 2024, then surged by 291.01% to $172.8 million in 2025, then surged by 43.78% to $248.5 million in 2026.
- The last three Assets figures came in at $248.5 million (Q1 2026), $172.8 million (Q4 2025), and $183.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | 238.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 238.21 Mn |
| Mar 31, 2026 | 248.47 Mn |
| Dec 31, 2025 | 172.81 Mn |
| Sep 30, 2025 | 183.45 Mn |
| Jun 30, 2025 | 30.13 Mn |
| Mar 31, 2025 | 38.12 Mn |
| Dec 31, 2024 | 44.20 Mn |
| Sep 30, 2024 | 53.80 Mn |
| Jun 30, 2024 | 61.89 Mn |
| Mar 31, 2024 | 71.37 Mn |
| Dec 31, 2023 | 83.94 Mn |
| Sep 30, 2023 | 28.34 Mn |
| Jun 30, 2023 | 35.44 Mn |
| Mar 31, 2023 | 42.67 Mn |
| Dec 31, 2022 | 50.90 Mn |
| Sep 30, 2022 | 52.51 Mn |
| Jun 30, 2022 | 59.41 Mn |
| Mar 31, 2022 | 68.49 Mn |
| Dec 31, 2021 | 81.14 Mn |
| Sep 30, 2021 | 116.93 Mn |